Latest Posts
About This Stock
More About This Stock
Read
Novartis Grabs Licenses On New Tech For Next-Gen Therapies For CAR-T
Article By:
Lorimer Wilson
Tuesday, May 2, 2017 3:30 PM EDT
The Belgian biotech Celyad announced that Novartis had gained non-exclusive rights to IP it has on allogeneic CAR-Ts, off-the-shelf cell therapies for cancer that could eventually prove superior to the autologous programs now lining up for approval.